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Abstract 
Identification of telomere binding region and ribozyme 
target site in human telomerase RNA 
 
 
Marie Yeo 
 
Department of Medical Science 
The Graduate School, Yonsei University 
 
 
Human telomerase RNA (hTR), an essential component of 
telomerase, has unique secondary structure consisted of several distinct 
structural domains as well as  template sequence which directs telomeric 
DNA synthesis at the ends of chromosomes. It is well established that 
hTR has to be accessible for both telomere  and telomerase catalytic 
subunit (hTERT) for the specialized reverse transcriptase activity of 
telomerase. Previous studies suggested that only small fragment (159 
nucleotides) of hTR is sufficient for the interaction with hTERT, but 
 2 
structural domains of hTR required for interaction with telomere have 
not been elucidated. Here, we report that at least, the 326 nucleotides 
fragment of hTR consisted of the  template, pseudoknot, and CR4-CR5 
domain is required to exhibit a binding capacity with telomere, and 
simultaneously display a telomerase activity in vitro reconstitution assay. 
Furthermore, targeted disruption of the template region with antisense 
oligonucleotide results in the complete blocking of the hTR-telomeric 
DNA binding, whereas CR4-CR5 disruption totally abrogate telomerase 
activity in vitro.  
Since the reactivation of telomerase is thought to be an essential step 
in immortalization of cells and tumor progression, it is suggested as a 
good target for anti-cancer strategies. Specific inhibition of telomerase in 
tumor cells leading to telomere shortening, and eventually, cell death has 
been demonstrated in recent papers. Ribozyme is a RNA molecule which 
possesses specific endoribonuclease activity and catalyzes the hydrolysis 
of specific phosphodiester bonds resulting in the cleavage of the RNA 
target sequences. Here, we evaluated a target site of hammerhead 
ribozyme in human telomerase RNA to inhibit telomerase activity. 
Hammerhead ribozyme targeting the template region of hTR efficiently 
cleaved human telomerase RNA in vitro. Stable transfectants of ribozyme 
 3 
showed degradation of hTR, and diminished telomerase activity. 
Moreover, ribozyme transfectants displayed significantly delayed 
doubling time than parental cells.  
In conclusion, we demonstrated that hTR interacted with telomeric 
DNA through a 326 nucleotides of hTR including template, pseudoknot, 
and CR4-CR5 domains with distinct roles in terms of telomere  binding 
and telomerase activity. The template region of hTR was the best target 
site for inhibition of telomerase activity, as anticancer strategy using 
ribozyme in human breast tumor cell. 
 
Key Words: Telomere, Telomerase, Human Telomerase Protein Component 
hTERT, Human Telomerase RNA Component hTR, Cancer, Ribozyme. 
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target site in human telomerase RNA 
 
Marie Yeo 
 
Department of Medical Science 
The Graduate School, Yonsei University 
 
 
I. INTRODUCTION 
 
Telomerase is a specialized reverse transcriptase that replenishes telomere 
through the adding of tandem repeats (TTAGGG) of telomeric DNA onto the 
ends of chromosomes1, 2. Telomeres are necessary for eukaryotic chromosome 
stability and the complete replication of chromosome end 3, 4 , 5. The termini of 
telomeric DNA cannot be fully replicated by the end replication problem of 
DNA polymerase, thus a net loss of telomere sequences occurs at each cell 
division 6,7. It has been proposed that this cumulative telomeric erosion is a 
 5 
limiting factor in replicative capacity and elicits a signal for the onset of 
cellular senescence 8, 9. To proliferate beyond the senescence checkpoint, cells 
must restore telomere length. This can be achieved by telomerase, which is 
inactivated in most normal somatic cell, but is reactivated in most cancer cells 
10, 11. Thus, telomerase plays an important role in both cellular senescence and 
especially in immortalization of transformed primary cells due to its pivotal 
role in unlimited cellular proliferation (Figure 1) 12.  
The current evidence of a strong correlation between telomerase 
activation, cellular immortalization, and cancer clearly identifies both 
telomere and telomerase as specific targets for anti-cancer therapy 13, 14. Table 
1 showed the various approaches to telomerase inhibition that are recently 
under investigation. Specifically, taking advantage of structural and functional 
similarities in telomerase and retroviral reverse transcriptase, reverse 
transcriptase inhibitors, such as nucleoside analogs, have been also used as 
inhibitor of telomerase activity 15, 16. An additional targeted strategy dealt with 
components of telomerase, hTERT and hTR. In fact, it has been shown that 
chemically modified oligonucleotides, such as phosphorothioate oligomers, 
peptides nucleic acids and hammerhead ribozymes targeting telomerase 
components reduced telomerase activity of tumor cells 17, 18, 19.     
 
c) Tumor cells
Cell Division
Replicative Senescence
Checkpoint (M1)
Telomere Crisis (M2)
a) Germline, Embryonic Stem Cells
b) Telomerase transduced cells
Hayflick Limit
T
elom
ere L
ength
Figure 1. Schematic figure of the telomere hypothesis of cellular aging and immortalization
based on Harley et  al. 12. The relationship between telomere length and cell divisions in 
normal somatic cells and tumor cells. In normal somatic cells, there exists at least two 
telomere-dependent mortality phases (M1 and M2). Replicative senescence is characterized 
by a checkpoint arrest trigged by a DNA damage response due to critical telomere loss. If 
cells lack this checkpoint, they can continue to divide, losing telomeric DNA until the crisis 
phases characterized by major telomere dysfunction, genetic instability and apoptosis. It 
illustrates telomere maintenance in immortal germline (a), in normal somatic cells 
immortalized by etopic expression of telomerase (b), and in tumor cells which have 
undergone growth control mutations and abnormal reactivation of endogenous
telomerase (c). 
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Telomerase RNA component
Antisense 23, 24
2-5A antisense 17, 19
Ribozyme 20, 21
* PNA 25, 26
Telomerase catalytic subunit
Dominant negative hTERT 27, 28
Reverse transcriptase inhibitor 29, 30
Ribozyme 31, 32
Reverse transcriptase inhibitor 15, 16
G-quadruplex stabilizer 42, 43
Feng et al., 1995; Kondo et al., 1998
Kondo et al.,1998, 2000
Yokoyama et al., 1998; Folini M et al., 2000
Norton et al., 1996; Shammas et al., 1999
Hahn et al, 1999; Zhang  et al., 1999
Strahl and Blackburn, 1996; Melana et el., 1998
Yokoyama et al., 2000; Ludwig et al., 2001
Gemez et al,1998; Stranhl et al, 1996
Han et al, 2000; Kerwin et al, 2000
Component   References
Table 1. Approaches for targeting telomerase in cancer therapy
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*PNA; Peptide Nucleic Acid
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Ribozymes are small catalytic RNA molecules possessing specific 
endonuclease activity. The catalytic sequences can be designed to specifically 
cleave a target RNA sequences by incorporating the flanking sequences 
complementary to the target. They are being increasingly considered and used 
as human gene therapeutic agent against human malignancies 20, 21, 22.  
The synthesis of telomeric DNA requires at least two components of  
telomerase: the protein catalytic subunit (hTERT) and the RNA subunit (hTR) 
(Figure 2). The RNA component of telomerase contains a short template 
sequence that specifies the telomere repeat, which is also essential for 
telomerase enzymatic activity. Recently, a secondary structure of the human 
telomerase RNA has been proposed based on a phylogenetic comparison 
analysis, and revealed that it contains several structural domains conserved in 
all vertebrates implying an evolutionary conservation of telomerase RNA 33. 
The conserved secondary structures are composed of several distinct domains 
including the template, pseudoknot, CR4-CR5, Box H/ACA, and the CR7 
domains (Figure 3, A). This finding suggested that a conserved structure of 
hTR may play an essential role in the regulation of telomerase activity. 
Human telomerase activity can be reconstituted by the addition of in 
vitro transcribed hTR to rabbit reticulocyte lysates (RRL) expressing hTERT 
34, MNase treated cancer cell lysate 35 or recombinant hTERT purified from  
AGUCAAUCCCAAUCUG
TTAG
GGTTAGGG
TTAGGG
Telomeric DNA
5’ 3’
hTR
hTERT
Figure 2. A model of human telomerase RNP assembly. Telomerase is a ribonucleoprotein
(RNP) composed of protein subunit hTERT and RNA subunit hTR. The large one 
represents hTERT catalyzing new telomere synthesis through the reverse transcription of 
template sequences of hTR. The RNA component hTR containing the template sequences 
interacts with both hTERT and end of telomere. The possessive cycles of telomere binding, 
elongation, and translocation add TTAGGG repeats to the 3’ telomeric terminus .
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baculovirus–infected insect cells 36. In vitro assembly reactions using deleted 
or site-directed hTR mutants suggested that the structural domains played 
critical roles in telomerase activation. Wright et al. reported that a minimal 
region required for the expression of telomerase activity is the nucleotides 
between +33-+325 37. Autexer et al. suggested a direct interaction between 
hTR and hTERT, based on the fact that 159 nucleotides of hTR were 
sufficient for the stable interaction with hTERT 38. The CR4-CR5 and 
pseudoknot domains have also been suggested as critical domains for the 
reconstitution of telomerase activity 39, 40. However, significance of each 
structural domain of hTR in binding with telomeric DNA and effect of this 
binding on telomerase enzymatic activity had not been elucidated.  
In this study, we present the minimal structural lengths of hTR that 
confers the ability to make hTR-telomeric DNA complex in vitro as well as 
the reconstitution of telomerse activity. To assess minimal structural region of 
hTR, we generated truncated hTR mutants based on the functional domains of 
hTR secondary structure. These mutants were then tested for the ability of 
binding with telomeric DNA utilizing modified electrophoretic mobility shift 
assay (EMSA) with single stranded telomeric  repeat sequences, (TTAGGG)n. 
The telomere binding capacity of each mutant was also directly compared to 
its reconstitutional ability of telomerase activity and hTERT binding ability. 
 11 
In order to make a complex of telomeric DNA and hTR, the results showed 
that hTR required the its major functional regions comprised the template, 
pseudoknot and CR4-5 domains. Moreover, we also found that each mutants 
displayed telomerase activity parallel to the binding capacity of the same 
mutant implying that the minimal hTR length contributes to both telomeric 
DNA binding and telomerase activation. Functional study using antisense 
oligonucleotide also suggested that there might be independent regulatory 
regions in terms of telomeric DNA binding and activation of telomerase on 
hTR structural regions by the results that targeted disruption on template 
region efficiently abrogated telomeric DNA binding and telomerase activity. 
However, targeted inhibition of CR4-5 region only exhibited the loss of 
telomerase activity. 
Based on the in vitro study results, we evaluated the ability of a 
hammerhead ribozyme targeted the hTR to inhibit the catalytic activity of 
telomerase. We verified the ribozyme specificity by means of its ability to 
cleave the synthetic RNA substrate. Subsequently, we examined whether the 
stable expression of ribozyme targeted the hTR inhibited telomerase activity, 
which resulted in growth retardation of breast tumor cell, MCF-7.   
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II. MATERIALS AND METHODS 
 
1. Identification of telomere binding region in human 
telomerase RNA 
 
A.  Preparation of hTR  
To investigate the role of the structural domains in human telomerase 
RNA, we generated truncated hTR mutants based on the proposed secondary 
structure of hTR 33. Full length or truncated mutants were obtained by PCR 
amplification of HT1080 genomic DNA with each oligonucleotides primers 
encoding the sequences of each domain of hTR as follows: D1 (+1-+183), 
(+1-+212), D3 (+1-+326), D4 (+1-+363), D5 (+1-+407), D6 (+1-+451), D7 
(+64-+451). The PCR products were cloned into pGEM-T vector (Promega) 
containing the T7 RNA polymerase promoter sequence at the 5’ end of the 
multiple cloning region. Full length or truncated mutants of hTR were 
transcribed in vitro using the RiboProbe transcription system (Promega) 
(Figure 3 B). 
 
B.  Preparation of hTERT  
The full-length cDNA of hTERT was kindly provided by Dr. S.C. Kim 
(Genoprot. Korea). Insert DNA containing the entire hTERT coding sequences 
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fused with a HA-epitope tag at C-terminal was subcloned into pCI neo vector 
at the sites of EcoR I – Sal I. hTERT-HA protein was synthesized by using a 
rabbit reticulocyte lysate transcription / translation system (TNT®  System; 
Promega) according to the manufacturer’s instructions. In brief, hTERT-HA 
cDNA was added to rabbit reticulocyte lysate (RRL) at a concentration of 0.04 
μg/ μL and incubated at 30℃ for 90 min. The translation product was used 
for the in vitro telomerase reconstitution. 
 
C.  In vitro telomerase reconstitution  
Human telomerase was reconstituted in 5 μL of reaction mixture 
containing 150 ng of in vitro transcribed hTR, 2 μL of in vitro synthesized 
hTERT in RRL and 2 μL of fresh RRL. The mixture was incubated at 30℃ 
for 90min and diluted by 10-fold in CHAPS lysis buffer (10mM Tris-Cl, pH7.5, 
1mM MgCl2 , 1mM EGTA, 0.1mM PMSF, 0.5% CHAPS, 10% glycerol). Five 
micro liters of this mixture was used for the telomerase enzyme assay.  
To determine the effect of antisense oligonucleotide on the assembly of 
active telomerase, 50 pmoles of oligonucleotide were incubated with the hTR 
at 30℃ for 15 min prior to the addition of in vitro synthesized hTERT 
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D.  TRAP assay   
The TRAP assay was performed as described by Kim et al. with some 
modifications 41. Briefly, for the extension of TS primer (5’-
aatccgtcgagcagagtt-3’), 5 μL of reconstituted telomerase was added to a 
reaction mixture containing 62.5 μM dNTP, 5 ng/μL TS, 125 μg/ml BSA in 
TRAP buffer (5mM Tris-Cl, pH 8.3, 0.37mM MgCl2, 15mM KCl, 0.00125% 
Tween 20, 0.25mM EGTA). After incubation at 30℃ for 60min, the sample 
was subjected to two-step PCR (94℃, 30s and 60℃, 30s) for 28 cycles with 5 
X 10 –21 M TSNT (5’-aatccgtcgagcagagttaaaaggccgagaagcgat-3’), 0.2 ng/μL 
NT (5’-atcgcttctcggcctttt-3’), 2 ng/μL ACX (5’-gcggcggcttacccttacccttacccta 
-3’), 62 uM dNTP, 0.16 μCi/ μL (3000Ci/mmole, Amersham Pharmacia, 
Piscataway, NJ), 2.5U Taq polymerase (GiBCO BRL, Grand Island, NY) in 
PCR buffer (1.5mM MgCl2, 20mM Tris-Cl, pH 8.4, 50mM KCl). The PCR 
product was resolved on 12% polyacrylamide gel at 340 V for 3hrs, and the 
gel was dried and visualized by autoradiography. The relative activity of the 
telomerase was determined using the following formula. TPG (%)=Sample 
[(T-B)/ CT]¸wild type [(T-B)/ CT] X 100 (TPG; telomerase activity, T; total 
intensity of telomerase-mediated bands, B; intensity of the negative control, 
CT; intensity of the internal control). 
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E.  EMSA  
To identify the binding ability of the hTR mutants to telomere, EMSA 
was performed by using 32P-labeled telomeric sequences, (TTAGGG)n. In 
standard binding reactions, 150 μg of the hTR mutants was incubated with 
1pmole of end labeled (TTAGGG)3 in 1ｘbinding buffer (50mM Tris-Cl, pH 
7.5, 5mM MgCl2, 1mM EDTA, 50mM NaCl, 1mM DTT, 5% glycerol, 66ng/ 
μL poly[dI.dC]) at 37℃ for 30 min. The binding complex was irradiated with 
15mJ in XL-1500 UV cross-linker (Spectronic  corporation, New York, USA) 
for 5min. Two micro liters of 80% glycerol were added to the 8 μL of the 
reaction mixture, and electrophoresis was conducted in a 1.5 % agarose gel or 
6% polyacrylamide gel in 0.5X TBE buffer (89mM Tris-borate, 2mM EDTA) 
at 4℃ for 4-5 hrs at 80 V. 
To determine the effect of antisense oligonucleotide on complex 
formation, 100-fold molar excesse of unlabeled oligonucleotide was added to 
the reaction mixture prior to adding labeled probe and incubated at 37℃ for 
15 min. Primer sequences used for the antisense analysis were as follows: 5’-
tcagttagggttagac-3’ for the template domain, 5’-gtttgctctagaat-3’ for the 
pseudoknot domain, and 5’-gctgacagagcccaact-3’ for the CR4-CR5 domain. 
Antisense oligonucleotide was designed to target the unpaired region in the 
functional domain of hTR based on the proposed secondary structure by Chen 
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et al. (Figure  3 A). 
 
F.  Immunoprecipitation    
Fifty microliters of assembly reaction mixture was precipitated by adding 
anti-HA mouse monoclonal antibodies (Santa Cruz Biotechnology, Inc) and 
70ul of protein G agarose (Santa Cruz Biotechnology, Inc) in IP buffer (50 
mM HEPES, pH7.6, 100 mM NaCl, 0.1% NP-40, 0.2 mM EGTA, 1 mM 
MgCl2, and 10% glycerol). Agarose pellet was washed in washing buffer(20 
mM HEPES, pH7.6, 20% glycerol, 10 mM NaCl, 0.2 mM EGTA, 1 mM 
MgCl2 , 0.1% NP-40, and 0.1% BSA). Two microliters, 10ul, and 30ul of 
beads were analyzed for TRAP, Western, and Northern analysis, respectively. 
 
G.  Western analysis  
Assembly reaction mixtures or immunoprecipitants were electrophoresed 
onto 8% SDS-PAGE gel. The gel was transferred to PVDF membrane in a 
buffer (39mM glycine, 48mM Tris base, and 20% methanol). The membrane 
was blocked in 5% skim milk, probed with 1:1000 diluted anti-HA primary 
antibodies, and incubated with 1:2000 diluted horseradish peroxidase-
conjugated secondary antibodies (Amersham). The membrane was visualized 
by ECL according to the manufacturer’s  instruction. 
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H.  Northern analysis 
The integrity and amount of hTR mutants were verified by northern 
hybridization analysis. To isolate RNA, assembly reaction mixtures were 
extracted with phenol: chloroform: isoamyl alcohol (25:24:1), and 
precipitated with 0.1 volumes of 3M sodium acetate, and 2.5 volumes of 
ethanol. The isolated RNA was electrophoresed onto 1.5% agarose–2.2M 
formaldehyde gel and transferred to a Hybond-N + membrane (Amersham). 
The membrane was probed with 32P-labeled oligonucleotides complementary 
to hTR nt+164 to nt+183. The blot was washed twice for 30min at room 
temperature in 0.1x SSC/0.1% SDS buffer and performed autoradiography 
 
2.  Ribozyme target sites in human telomerase RNA 
 
A.  Ribozyme synthesis and in vitro cleavage assay  
Hammerhead ribozymes were designed against seven NUX sequences 
(where N can be any ribonucleotides, and X can be any ribonucleotides 
excepting guanine) located in open loops on hTR secondary structure. Using 
four or five antisense nucleotides on each side of catalytic core, they designed 
to cleave 3’ of the Cs at position 46, 156, 160, 275, 313, 317, and 360 of hTR. 
As shown figure 9, the ribozymes were named R1-7 from 5’ end of hTR target 
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site and Rm (mis-matched ribozyme). The ribozymes for in vitro cleavage 
reaction were obtained by in vitro transcription of PCR product. A set of 
oligomers for PCR amplification was designed to make the ribozyme template 
containing T7 RNA polymerase promoter sequence at 5’ upstream of 
ribozyme. One set of primer contained a T7 RNA polymerase promoter 
sequence followed by the 5’ half of the ribozyme sequences; the other primer 
contained the antisense sequences of ribozyme. The primers used for each 
ribozyme were as follows: 5’-tgtaatacgactcactataggagggttactgatgagtccgtg-
3’and 5’-tttttgtttcgtcctcacggactcatcagtaaccct-3’for R1; 5’-tgtaatacgactcactat 
aggtagaatctgatgagtccgtg-3’and 5’-caccgttttcgtcctcacggactcatcagattcta -3’for 
R2; 5’-tgtaatacgactcactatagggctctactgatgagtccgtg-3’and 5’-gttcattttcgtcctcacgg 
actcatcagtagagc-3’for R3; 5’-tgtaatacgactcactataggctgacactgatgagtccgtg-3’and 
5’-gttgggctttcgtcctcacggactcatcagtgtcag-3’for R4; 5’-tgtaatacgactcactataggcg 
gctctgatgagtccgtg-3’and 5’-gctctgtttcgtcctcacggactcatcagagccg-3’for R5; 5’-
tgtaatacgactcactataggcctccgctgatgagtccgtg-3’and 5’-ggcttctttcgtcctcacggactc 
atcagcggagg-3’for R6; 5’-tgtaatacgactcactatagggcctctgatgagtccgtg-3’and 5’-
aggcctttttcgtcctcacggactcatcagaggc-3’for R7; 5’-tgtaatacgactcactataggtgaaaa 
actgatgagtccgtg-3’and 5’-ttccagtttcgtcctcaaggactcatcagtttttca-3’for Rm. The 
primer sets were mixed to form a hemiduplex, and a PCR amplification of 25 
cycles was performed at 94 ℃ for 1 min, 40 ℃ for 1 min, and 72 ℃ for 
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1min. The ribozyme transcript was obtained by in vitro transcription of PCR 
product using a T7-Mega shortscript kit (Amion, Inc., Austin, TX).  
To produce a synthetic RNA substrate, D6 were transcribed in the 
presence of a-32P UTP using the RiboProbe In Vitro transcription system 
(Promega). The ribozyme and substrate RNA were mixed at 5:1 molar ratio in 
10 ul reaction volume containing 50mM Tris-HCl, pH 7.5, 10 mM MgCl2 and 
1mM EDTA. The mixture was incubated at 28 ℃ overnight and stopped by 
the addition of equal volume of stop buffer. The reaction mixture was 
electrophoresed in a 6% polyacrylamide-7M urea gel. The gel was dried and 
visualized by autoradiography.  
 
B.   Construction of the ribozyme expression vector and transfection 
Two single-stranded oligodeoxynucleotides were synthesized in a way 
that the 42bp ribozyme contained franking EcoRI restriction sites on both ends 
(5’-tgtgtaatacgactcactataggagggttactgatgagtccgtg-3’ and 5’- tttttgttttcgtcctcacg 
gactcatcagtaaccct-3’ for R1; 5’-tgtaatacgactcactataggtgaaaaactgatgagtccgtg-3’ 
and 5’-ttccagttttcgtcctcaaggactcatcagtttttca-3’ for Rm). The oligonucleotides 
were annealed and cloned to pcDNA3 (Invitrogen, San Diego, CA). The 
sequence and orientation of the ribozyme in the vector were confirmed by 
DNA sequencing.  
 20 
DOTAP-mediated transfection of MCF-7 cells was performed according 
to the manufacturer’s instructions. Briefly, cells seeded at a density yielding 
50% confluency, were transfected with 5ug of pcDNA·Rm or pcDNA·R1 
plasmid with 30ug of DOTAP. Six hours after transfection, the culture 
medium was replaced by selection medium containing G418 with a final 
concentration of 1.5mg per ml. The transfected cells were exposed to G418 
for 1 month. 
 
C.  Characterization of transfectants 
(A). RT-PCR analysis of ribozyme and hTR expression  
Total RNA was isolated from the transfectants and the parental cells, 
and was reverse-transcribed by First Strand cDNA Synthesis kit (MBI, 
Hanover, MD) according to the manufacturer’s instructions. To analyze 
ribozyme expression, the cDNA was amplified by using T7 and antisense 
primers complemented to 3’ end of ribozyme (5’-tttttgtttcgtcc-3’ for R1; 5’-
ttccagtttagtcc-3’ for Rm) and by performing 30 cycles of PCR (94℃ for 
30s , 48℃ for 30s and 72℃ for 30s). For the analysis of hTR and ß-actin 
expression, PCR amplification of 25 cycles was performed at 94℃ for 30s, 
59℃ for 30s, and 72℃ for 30s using the primers (5’-
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gctctagagggttgcggagggtgggcct-3’ and 5’-ctgcagtccccgggaggggcgaa-3’ for 
hTR, 5’-caggtcatcaccattggcaatgagc-3’ and 5’-cggatgtccacgtcacacttcatga-3’ 
for ß -actin).  
 
(B).  Telomerase activity analysis 
   Telomerase activity was measured by TRAP assay as above described 
in Materials and Methods D.    
 
(C). Population doubling 
To evaluate the proliferation rate of transfactants, cells were seeded at 
6well dish with 2x104 densities per well. After culture for 1 week, cell 
numbers were counted by trypan blue staining. The population doubling 
(PD) / day was calculated by the following formula; PD/day=log2 (total cell 
number-2x104) / 7day 
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III. RESULTS 
 
1. The minimal requirement of hTR for telomeric DNA binding was 
326nt.  
As shown in Fig. 3 A, the secondary structure of hTR is composed of 
template sequences and four conserved structural domains, namely, 
pseudoknot, CR4-CR5, Box H/ACA, and the CR7. This remarkable 
conservation of hTR structure implies an important role in telomerase 
function. To identify the significant structural domain of hTR in telomerase 
activation, we generated seven hTR truncation constructs based on the 
secondary structure. Truncations of hTR were designed to delete each 
structural domain in a stepwise way as shown a line diagram in Fig. 3 B. The 
size and integrity of in vitro transcribed hTR transcripts were confirmed by 
agarose electrophoresis with size marker (Figure 3 C). 
We first identified telomere binding region of hTR by EMSA using in 
vitro transcribed hTR and the single strand telomeric  repeated sequence, 
(TTAGGG)n. The optimum temperature for the telomeric DNA–hTR 
complex was found to be 37℃ compared with the other temperatures 
examined (24℃, 4℃, and 0℃; data not shown). To observe the effect of 
telomeric length on hTR-telomeric DNA complex formation, variable length  
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Figure 3. Secondary structure of hTR and schematic representation of hTR mutants. A. 
Secondary structure of hTR is composed of telomeric template sequence and several 
conserved domains including pseudoknot, CR4-CR5, Box H/ACA, and the CR7 domains 
(in box). Red regions showed the location of antisense oligonucleotides against template, 
pseudoknot, and CR4-CR5 domain, respectively. B. hTR mutant constructs are 
represented schematically with respect to the conserved structural domains. hTR mutants 
are deigned to serially truncate structural domains from 3’or 5’end of hTR and denoted 
by the transcribed nucleotides within hTR. C. hTR mutants are in vitro transcribed with 
T7 RNA polymerase and electrophoresed on 1.5% agarose-2.2M formaldehyde gel to 
verify the accurate sizes and amounts. .
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of (TTAGGG)n were added to the reaction (Figure 4 A). The strongest 
complex formation was observed only with (TTAGGG)3 (lane 2). Shorter 
(lane1) or longer (lanes3, 4, and 5) telomeric sequences than 18mer did not 
form a sufficient complex compared to 18mer, (TTAGGG)3. This result 
suggests that the length of the telomeric sequence was found to be critical for 
binding between hTR and telomeric DNA. Next, We identified the minimal 
structural domains of hTR required for telomere binding utilizing EMSA with 
hTR mutants and (TTAGGG)3 (Figure  4 B, top). A binding complex was not 
observed in D1 (1-183), D2 (1-212) and D7 (64-451). The RNA-DNA 
complex formation increased gradually from D3 (1-326) to D6 (1-451). 
Mutant D3 (1-326), D4 (1-363) and D5 (1-407) showed 13.2%, 27.4% and 
14.6% of the telomeric DNA binding activity comparing to the wild type D6, 
respectively. Thus, these EMSA results suggested that the minimal 
requirement of hTR for telomeric DNA binding was 326nt fragment, which 
contained the template, pseudoknot, and the CR4-5 domain. To monitor the 
amount and integrity of input hTR mutants in binding assay, we isolated RNA 
from binding mixture and performed northern hybridization with hTR-specific  
probe (Figure 2B, bottom). We observed that the levels and integrities of 
hTR mutants in binding assay were not grossly different. In spite of equal 
RNA amount, mutant D5 showed more reduced complex formation than the 
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shorter mutant, D4. Thus, we tested D5 as a putative dominant negative 
mutant in the next experiment. 
 
2. Telomerase reconstitution activity of hTR mutants correlated with the 
telomere  binding capacity.  
To analyze the ability of each hTR mutant to reconstitute telomerase 
activity, we performed in vitro telomerase reconstitutional assay in an RRL 
system expressing hTERT and verified telomerase activity by TRAP assay. 
To establish the optimal reconstitution reaction, we examined the dose-
response relationships of the recombinant components. Telomerase activity 
was shown to increase gradually by adding amount of two essential 
components of telomerase, hTR or hTERT (Figure 5 A). Active telomerase 
assembly was also found to be dependent on the presence of fresh RRL in a 
dose-dependent manner. Thus, we optimized the in vitro telomerase 
reconstitution reaction by adding 150 ng of hTR transcript, 2 μ L of rabbit 
reticulocyte lysate expressing hTERT, and 2 μ L of fresh rabbit reticulocyte 
lysate. The different hTR mutants were introduced into in vitro synthesized 
hTERT in the presence of fresh RRL (Figure 5 B). The activity of the 
reconstituted telomerase was measured using the TRAP assay. The results 
showed that D1 (1-183), D2 (1-212) and D7 (64-451) had no activity. D3 (1- 
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Figure 4. Complex formation between in vitro transcribed hTR and telomeric DNA. A. Effect 
of telomeric DNA length on DNA-RNA complex formation was evaluated by using different 
lengths of 32P-labeled (TTAGGG)n (n=2, lane1; n=3, lane 2; n=4, lane 3; n=5, lane 4; n=6, 
lane 5). B. EMSA was carried out using 32P-labeled telomeric DNA, (TTAGGG)3 and various 
truncated hTR mutants transcribed in vitro. One pmole of 32P-labeled probe was incubated 
without (lane 1) or with (lane 2-8) the truncated hTR mutants. Reactions were resolved in 
1.5 % agarose gel and visualized by autoradiography (top). After binding reaction, isolated 
hTR mutants were subjected the northern hybridization analysis with 32P-labeled 
oligonucleotides complementary to hTR nt+164 to nt+183 (bottom).                   .       
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326), D4 (1-363) and D5 (1-407) showed 46%, 58.0 %, and 32.0% of the 
telomerase activity comparing to the wild type D6, respectively (Figure 5 B). 
The results showed that at least, 326nt of hTR is essential for telomerase 
activity in RRL reconstitution system, consistent with the previous studies 34, 
37. We also found that telomerase activity correlated with the telomere binding 
capacity in each mutant, implying that the minimal hTR length contributes to 
both telomeric DNA binding and telomerase enzymatic activ ity. However, 
there were some discrepancies in degree of both abilities. For example, 
mutant D3 expressed 46 % of telomerase activity of wild type hTR, but is 
only exhibited 13.2 % of telomere binding ability of wild type hTR. To 
exclude the experimental bias from single concentration point of hTR, we 
tested three different concentrations of hTR mutant in binding assay (data not 
shown) and telomerase reconstitution assay (Figure  5 B). Increment of hTR 
concentration did not change activities in both assays, suggesting that ability 
of hTR to make few complexes with telomeric DNA sufficient for confer the 
telomerase activity. This finding was also observed in functional study using 
antisense oligonucleotides (Figure 5 A and B). Regardless of complete 
inhibition of telomere binding by anti-template oligonucleotide, telomerase 
activity still exhibited 29.6 % of telomerase activity of wild type hTR. 
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Figure 5. In vitro reconstitution of telomerase activity. A. Standard assay was performed 
with 150 ng hTR, 2 μL of in vitro synthesized hTERT and 2 μL of fresh RRL. In vitro 
reconstitution of telomerase was evaluated with various amounts of hTR, hTERT, and 
fresh RRL (lanes 1-5; 0, 10, 50, 150, or 300 ng of hTR, lanes 6-9; 0, 0.5, 1, or 2 μL of 
hTERT synthesized in vitro, lanes 10-12; 0, 1, or 2 μL of fresh RRL). B. in vitro 
reconstitution assay was performed with various amounts of in vitro transcribed hTR (left; 
75ng, middle; 150 ng; right; 300 ng). The telomerase activity of in vitro reconstitution was 
measured by TRAP assay. .
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3. Structural domains of hTR played functionally a distinct role in 
telomere binding and hTERT binding.  
To evaluate the ability of each hTR mutant to associate with hTERT, 
assembly reaction mixtures were immunoprecipited with HA-antibody to HA 
tag located at the carboxy terminus of hTERT, and subjected to western and 
northern analysis (Figure 6 C). hTERT binding activity of each hTR mutant 
was  compared to  the  telomerase  enzymatic  act ivi ty  of  HA -
immunoprecipitates (Figure 6 A). Total hTERT level in assembly reaction 
mixture and pulled down precipitates with HA antibody were same in all 
mutants (Figure 6 B). In spite of the same input amount in all assembly  
reaction fractions, mutant D7 spanning nucleotides 64-451 did not 
coimmunoprecipitate with hTERT. These results suggest that 1-64nt structural 
region of hTR plays a critical role for binding with catalytic subunit of 
telomerase and mutant D1 spanning 1-183 is sufficient for interaction with 
hTERT. Furthermore, it suggests that minimal structural domains of hTR play 
functionally a distinct role in telomere binding and hTERT binding.  
We summarized the relative ratio of the enzymatic activity, telomeric 
DNA binding and hTERT binding of each hTR mutant in Table  2. There was 
a difference of structural length of hTR required for hTERT and telomere 
binding, respectively. On the contrary, minimal sequences of hTR required for  
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Figure 6. Telomerase enzymatic activities and hTERT binding abilities of hTR mutants. 
Different mutants were reconstituted with hTERT containing a HA tag, and were 
subjected to an anti-HA immunoprecipitation. A. Telomerase activity analysis of the anti-
HA immunoprecipitants by TRAP assay. B. Before (top) or after (bottom) the 
immunoprecipitation, western analysis was performed with anti-HA monoclonal antibody. 
C. Before (top) or after (bottom) immunoprecipitation, isolated RNA was subjected to 
northern hybridization analysis with hTR-specific probe.                                      .                                                         
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telomerase activity and the telomere binding were exactly coincided. These 
findings demonstrated that telomere binding of hTR directly influences the 
reconstitution of telomerase activity. Hence, in a sense of determining the 
minimal requirement for telomerase activity reconstitution, hTR-telomere 
binding is a limiting factor rather than hTR-hTERT binding. 
  
4. Targeted disruption of the template and CR4-CR5 region resulted in 
efficient inhibition of the hTR-telomeric binding and telomerase activity.      
As shown in Fig. 2 and 3, the minimal sequence of hTR required for 
telomere binding and telomerase activity contains three functional domains, 
i.e., the template, pseudoknot, and CR4-CR5 domains. To evaluate the role of 
the each functional domains in the minimal hTR sequences, we used antisense 
oligonucleotides targeting each domain.  Furthermore, these antisense 
oligonucleotides were tested to determine any possible role  as a telomerase 
inhibitor. Antisense oligonucleotides were designed to target the unpaired 
region in template, pseudoknot, or CR4-CR5 domain of hTR based on the 
proposed secondary structure (Figure  3 A). Figure 7 A shows that wild-type 
hTR forms a strong complex with the 32P-labeled telomeric sequences of 
(TTAGGG)3 (lane 1). This RNA-DNA complex formation was competitively 
inhibite by adding a non-labeled homologous competitor (lane 2), whereas it  
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was not inhibited by any of the equal molecular weight, nonspecific  primers 
[(TGTGAG)3, lane 3; and (TTGGAG)3, lane 4]. This finding suggested that the 
formation of the hTR-telomere complex is mediated by a sequence-specific  
recognition. Anti- template oligonucleotides completely abolished the retarded 
RNA-DNA band (lane 5), while anti-CR4-CR5 oligonucleotides reduced only 
4% (lane 7). On the other hand, anti-pseudoknot oligonucleotide enhanced the 
complex formation (lane 6). These results suggested that the template region is 
a good target site for the inhibition of telomere binding.  
We analyzed the effects of these antisense oligonucleotides on telomerase 
activity by TRAP assay (Figure 7 B). Anti-CR4-CR5 and anti-template 
oligonucleotides effectively inhibited telomerase activity by 90.6% and 70.4%, 
respectively. Anti-pseudoknot oligonucleotides also reduced telomerase 
activity by 25.9% compared with that of the wild type. Since the antisense 
oligonucleotides showed different effects in the EMSA and the TRAP assay, 
these findings demonstrate that each structural domain play distinct roles in 
telomere binding and telomerase activity. 
 
5. D5 is a putative dominant negative mutant of hTR. 
 As shown in Fig. 4 A and 6 A, mutant D5 reduced telomere binding and 
telomerase activity than the shorter mutant, D4. We assumed D5 to be a 
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Figure 7. Effect of antisense oligonucleotides on the formation of RNA-DNA complex and 
telomerase activity. A. EMSA was performed in the absence (lane 1) or presence (lanes 2-7) 
of competitive primers or antisense oligonucleotides. hTR was incubated with non-labeled 
homologous competitor (lane 2), nonspecific primer [(TGTGAG)3, lane3: (TTGGAG)3, 
lane4], anti-template oligonucleotide (lane 5), antipseudoknot oligonucleotide (lane 6), or 
anti-CR4-CR5 oligonucleotide (lane 7) prior to adding the 32P-labeled probe. B. After 
incubating hTR with antisense oligonucleotides, hTERT was added to the reaction and the 
TRAP assay was performed. C. relative quantitation of the degree of inhibition by antisense 
oligonucleotides.                                                           .   
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dominant negative mutant against wild type hTR. The addition of D5 to wild 
type hTR resulted in a gradual decrease of telomerase activity, in a dose-
dependent manner (Figure 8 A). Telomerase activity of the wild type was 
also completely inhibited by adding the equal amount of D5. As shown in Fig. 
2 and 3, the alteration of the hTR structure in D5 inhibited the assembly of 
wild type telomerase significantly. These results suggested D5’s role as a 
putative dominant negative mutant, which inhibits wild type hTR. 
 
6. Specific cleavage of a synthetic RNA substrate by the R1 ribozyme  
Seven kinds of hammerhead ribozyme were designed to target the NUX 
sequences (where N can be any ribonucleotides, and X can be any 
ribonucleotides excepting guanine) in human telomerase RNA, base on the 
open loops in the proposed secondary structure. First, we studied whether the 
seven kinds of ribozyme could cleavage the RNA substrate efficiently in cell-
free system. A 32P-labeled hTR RNA substrate of 451bp was mixed with each 
ribozyme at a molar ratio of 1:5, and incubated in cleavage reaction buffer at 
28 ℃ for 16hrs. As shown in Fig. 9, reaction without ribozyme and reaction 
with a mis-matched ribozyme did not show any cleaved fragments. Ribozyme 
R1 efficiently cleaved the 451-bp telomerase RNA substrate into 362 and 45 
bp fragments. The ribozyme R2, 6, and 7 showed cleavage activity, while  
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Figure 8. Inhibition of wild type hTR by D5 mutant. Inhibition of wild type hTR by mutant 
D5 was assayed by TRAP assay (A). Wild type hTR (150 ng) was incubated with 0, 18.7, 
37.5, 75, or 150 ng of D5 mutant prior to adding RRL expressing hTERT. The 
reconstituted telomerase was subjected to TRAP assay.                                   .
Figure 9. Target sites of ribozymes against hTR and in vitro cleavage assay.  Hammerhead 
ribozyme were designed against seven NUX sequences in open loops on hTR secondary 
structure and represents in red. In vitro cleavage assay was performed with a -32P UTP 
labeled hTR substrate and ribozymes targeted to different sites of hTR. The reaction 
mixture was eletrophoresed in 6% polyacrylamide-7M urea gel.                    .
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ribozyme R3, R4, and R5 did not show any RNA substrates cleavage effect. 
 
7. Inhibition of telomerase activity by the exogenously delivered - 
ribozyme  R1  
For the screening of potency of the ribozymes, the ribozymes were 
synthesized exogenously and delivered using cationic loposome. The 
ribozymes were introduced to human breast tumor cell line MCF-7 with 
DOTAP. At 72hrs after administration of ribozyme, telomerase activity was 
determined by TRAP assay of cell lysates. Telomerase activity was 
diminished when ribozyme R1 was introduced (Figure 10). DOTAP alone or 
mis-matched ribozyme did not induce any effect on telomerase activity. None 
of the other ribozymes showed any significant change of telomerase activity 
comparing to that of control cell. It was thus concluded that ribozyme R1 was 
the most promising in the transfection study.  
 
8. Degradation of hTR by stable expression of ribozyme R1 attenuated 
telomerase activity  
 We subcloned the ribozyme R1 or Rm sequences into pcDNA3 vector 
and introduced it into MCF-7. The transfectants were selected by selection 
medium containing G418 to a final concentration of 1.5mg per ml for 1month.  
No          R1   R2    R3   R4   R5  R6   R7DO
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Figure 10. Inhibition of telomerase activity by exogenous delivery of 
ribozyme R1 RNA into human breast tumor cell line MCF-7. Five 
microgram of in vitro transcribed ribozyme was transfected with DOTAP 
into MCF-7 cell, and incubated for 72 hours. Ribonucleoprotein was 
extracted from transfectants and analyzed telomerase activity by TRAP 
assay. 
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After 1 month of selection, 8 Rm clones and 16 R1 clones were obtained from 
transfectants. To evaluate the expression of ribozyme and hTR from each 
clone, RT-PCR was performed with hTR, and ribozyme-specific primers 
(Figure 11). We confirmed that all clones of MCF-7 stably expressed the 
ribozyme either R1 or Rm. Rm-expressing clones did not show any change in 
hTR expression compared with that of parental cells. On the contrary, hTR 
expression was significantly reduced in clones which expressed ribozyme R1 
suggesting that ribozyme R1 successfully degraded hTR RNA. In some clones 
(clone 4, 5, 6, 9, and 12), hTR expression was detectable feebly. Telomerase 
activity of each transfectants was also measured by TRAP assay (Figure 12). 
Telomerase activity of R1 transfectant was dramatically attenuated compared 
with parent or Rm transfectants, although the activity level differed in the 
clones. Clone 1, 2, 3, 7, 8, 12, and 14 showed the undetectable level of 
telomerase activity, while clone 6, 9, and 15 still expressed a weak telomerase 
activity. Telomerase activity in transfectants correlated well with the 
remaining hTR expression level (Figure 12, bottom) suggesting that specific 
degradation of hTR by ribozyme R1 resulted in the inhibition of telomerase 
activity.  
 
 
Figure 11. Specific degradation of hTR by stable expression of ribozyme R1. 
Ribozyme Rm or R1 expression vector was transfected into MCF-7 cell. Clones 
were selected with selection media containing G418 for 1 month. Total RNA was 
isolated from each clone and performed RT-PCR with b-actin, ribozyme , and 
hTR-specific primers.
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Figure 12. Degradation of hTR by stable expression of ribozyme R1 inhibited 
telomerase activity in human breast tumor cell line MCF-7. Ribonucleoprotein
was extracted from transfectants and analyzed telomerase activity by TRAP 
assay. Low panel showed hTR expression of transfectants.                    .
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9. Clones with attenuated telomerase activity showed reduction of 
replicative capacity.  
To evaluate anti-proliferative effect of ribozyme R1, we measured 
population doubling (PD)/day. In Fig. 13 A, parental cells proliferated at the 
rate of 0.69 PD/day, and Rm transfectant showed 0.68 PD/day similar to that 
of parent cells. On the contrary, R1 transfectants showed a significantly  
delayed growth rate of 0.48 PD/day. Especially, clone 2 and 7 showed a half 
of the proliferation rate of parental cells, whereas clone 15 steadily 
proliferated at the level of the parental cells. Replicative capacity of 
transfactants paralleled with the level of telomerase activity (Figure 13 B). 
The results suggested that attenuation of telomerase activity by stable R1 
ribozyme expression resulted in growth inhibition of MCF-7 cell line.  
 
 
 
 
 
 
 
 
 
00.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0 20 40 60 80 100 120 140 160
Telomerase activity
Pr
ol
ife
ra
tio
n 
(P
D
/d
ay
)
Figure 13. Anti-proliferative effect of ribozyme R1 and relationship between 
telomerase activity and cell proliferation rate. After 2 months of transfection, cells 
were seeded in 6 well dish and cultured for 1 week, and then cell number was counted. 
The population doubling (PD)/day was calculated by the formula, PD/day=log2 (total 
cell number-2x104)/7day (A). Proliferation rate of each transfectant was compared 
with its telomerase activity (B). .
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IV. DISCUSSION 
 
Telomerase accessibility to telomere is essential for the synthesis of new 
telomeric sequences. Since hTR carries the template sequence complementary 
to telomeres, hTR would appear to be the most responsible subunit among the 
telomerase components in terms of access to telomeres. To explore the direct 
interaction between hTR and telemeres, we developed an EMSA using in vitro 
transcribed hTR and 32P-labeled telomeric-repeated sequences. The length of 
the telomeric sequence was found to be critical for binding between hTR and 
telomeric DNA. Shorter sequences than 18mer were too short to make a stable 
base pair with hTR, whereas longer sequence than 18mer would form 
secondary structures themselves, e.g., the G-quartet 42, 43. 
Previous studies using different telomerase reconstitution systems 
discovered roles of the functional domain of hTR in both telomerase activity 
and interactions with other telomerase components. Narayanari et al. reported 
that nucleotides +44-+203, which contains the template and pseudoknot 
domains, is the minimal sequences required for telomerase activity in a 
telomerase reconstitution assay using MNase treated human cell extract 35. 
Another group also suggested that nucleotides +33-+325 of hTR, which 
contains the template, pseudoknot and CR4-CR5 domains were the minimal 
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requirement for telomerase activity in an RRL system expressing hTERT 37. In 
particular, the integrity of CR4-CR5 and the pseudoknot structure were found 
to be critical for the reconstitution of telomerase activity in studies using 
truncated or sequence-substituted hTR mutants 39, 40. Direct interaction of 
hTR-hTERT was also investigated by using an in vitro telomerase 
reconstitution assay. Autexier et al. reported that 159nt of hTR was sufficient 
for a stable interaction with hTERT and found that two distinct hTERT-
binding sites exist at nucleotides + 33- +147 which contains the template 
region and a part of the pseudoknot domain, and at +164- +325 which 
contains the pseudoknot domain in part and the CR4-CR5 domain of hTR 38. 
Interestingly, different structural length of hTR is required for hTERT binding 
and telomerase activity, and the telomerase enzymatic activity needs much 
longer fragment of hTR than hTERT binding, which implied that there are 
other regulatory events excepting hTERT binding to confer telomerase 
enzyme activity. Thus, we focused on interaction between hTR and the 
telomeric DNA. Results showed that the minimal region of hTR required for 
telomere binding is up to 326nt, which contains the template, pseudoknot and 
CR4-5 domain. We also confirmed that this 326nt of hTR is critical for the 
assembly of telomerase activity. These findings demonstrated that telomere 
binding of hTR directly influences the reconstitution of telomerase activity. 
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Hence, in terms of determining the minimal requirements for the expression 
of telomerase activity, the present study showed that hTR-telomere binding is 
a limiting factor rather than hTR-hTERT binding. 
Many experiments have been conducted with a view to inhibit 
telomerase in cell culture system and in animal models. Application of reverse 
transcript inhibitors such as azidothymidine (AZT) and dideoxyguanosine 
(ddG) was found to lead to telomere shortening 15, 16. Telomerase-targeting 
antisense oligonucleotide induced apoptosis, differentiation of cancer cells 
and reduced tumorigenicity 17. We evaluated the role of each domain of hTR 
in telomere binding and in the reconstitution of telomerase activity with 
antisense oligonucleotides. Furthermore, these antisense oligonucleotides 
were tested to determine any possible role as telomerase inhibitors.  
Antisense oligonucleotides were designed to target the unpaired region in 
template, pseudoknot, or CR4-CR5 domain of hTR based on the proposed 
secondary structure by Chen et al. 33. Previous efforts have demonstrated that 
conserved domains of hTR played a distinct role in telomerase activation. For 
example, the first, sequence 5’-CUAACCCU-3’ in the template region of hTR 
provided a template sequence for the synthesis of new telomeric repeats 44. In 
this study, we demonstrate that the template region plays an important role in 
telomerase reconstitution not only by serving as a template, but also by 
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binding to the telomeric DNA. The pseudoknot domain consisted of three 
helix structures that stabilize the secondary structure 45. This domain was 
reported to be required for telomerase activation and assembly 39. The present 
study showed that the disruption of the pseudoknot domain by antisense 
oligonucleotide reduced telomerase activity, but in contrast, it enhanced 
telomere binding of hTR. These findings suggest that the pseudoknot domain 
might contribute to binding with hTERT, and that this domain is essential for 
telomerase activity, whereas it did not grossly influence the binding activity to 
telomeres. Antisense oligonucleotide targeting the pseudoknot domain might 
stabilize the secondary structure of hTR resulting in the enhancement of stable 
binding with telomeres. 
The CR4-CR5 domain lies downstream of the pseudoknot domain, and 
is composed of a stem-loop structure. The roles of the CR4-CR5 domains 
have not been demonstrated clearly, but truncated mutant without CR4-CR5 
domain did not have telomerase activity 40. CR4-CR5 domain has an open 
long single strand in its loop structure. Therefore we considered this region as 
a good target site for telomerase inhibition. We found that the antisense 
oligonucleotide targeting CR4-CR5 domain partially inhibited telomeric 
DNA-hTR binding, but completely inhibited its enzymatic activity. It was also 
reported that telomerase activity can be reconstituted in the presence of two 
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inactive, nonoverlapping fragments of hTR 38. These fragments are composed 
of the pseudoknot and the CR4-5 domains. In our study, antisense 
oligonucleotides targeting the pseudoknot and the CR4-5 domains inhibited 
the reconstitution of telomerase activity, whereas they did not influence 
telomere binding ability. This finding suggested that two functional domains 
(pseudoknot, and CR4-CR5 domains) are more critical for binding with 
hTERT than binding with telomeres.  
As shown in Fig. 4 and 6, the alteration of the hTR structure in D5 
inhibited the assembly of wild type telomerase effectively. These results 
suggested D5’s role as a putative dominant negative mutant, which inhibits 
wild type hTR. Although it had more 44nt at the 3’-terminus than D4 (1-363), 
D5 showed less telomere binding ability and enzymatic activity than D4. At 
this point, more detailed function study of D5 remains to be done, but at least, 
it can be suggested that D5 behaves as a dominant negative mutant though 
dimerization or polymerization with native hTR. Lingner et al. showed that 
telomerase RNA is assembled into active telomerase as a dimeric structure 46. 
Therefore, a telomerase heterodimer composed of wild type and mutant 
telomerase RNA might be inactive compared with the wild type homodimer. 
The 363-407 sequences of D5 remained as a single stranded overhang, which 
does not form a natural secondary structure. The single stranded overhang 
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might affect wild type hTR by aberrant base pairing with hTR, which this 
induce dysfunction of wild type hTR. Currently, we are investigating whether 
D5 can inhibit wild type hTR in cancer cells.     
Specific inhibition of telomerase in tumor cells led to telomere 
shortening, and eventually, to cell death 15, 16, 17, 18, 19. Here, we studied anti-
telomerase effect of hammerhead ribozyme targeting telomerase RNA 
component. Telomerase activity is not associated with the expression level of 
telomerase RNA in some tumors and cells. However, the crucial role of the 
RNA component in telomere shortening has been demonstrated in  
telomerase RNA knock mouse 47. Thus, we reasoned in this experiments that 
the breakdown of telomerase RNA by the ribozymes must lead to the 
attenuation of telomerase activity. because telomerase RNA is a direct 
participant in the telomerase complex as an essential element. We 
demonstrated that the reduction of telomerase RNA expression was associa ted 
with the attenuation of telomerase activity.  
 We chose the 7 NUX sequences in telomerase RNA including template 
region. Six target sites of telomerase RNA excepting template region were not 
cleaved efficiently by hammerhead ribozyme. For the ribozymes to recognize 
and catalyze the target sites, the target region must be sufficiently exposed on 
the outer surface of the molecule. Based on the data that ribozyme R1 
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targeting the template region reduced the telomerase activity most efficiently, 
the template region must be located at the outer surface of telomerase 
molecule.  
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V. CONCLUSION 
 
We first demonstrated 326 nucleotides of hTR spanning the template, 
pseudoknot, and CR4-CR5 domains exhibited a binding capacity with 
telomere and a telomerase activity in vitro reconstitution assay. This finding 
suggested that telomere binding ability is critical for telomerase enzymatic 
activity. Furthermore, targeted disruption of the template region of hTR 
resulted in the complete blocking of the hTR-telomeric binding, whereas 
disruption of CR4-CR5 totally abrogated telomerase activity in vitro. It is 
suggest that each functional region may underlie in different regulation in a 
sense of telomere binding and telomerase activity. In ribozyme study, the 
template region of hTER was a good target for inhibition of telomerase 
activity, as anticancer strategy using ribozyme in human breast tumor cell. 
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국문요약 
 
사람의 telomerase RNA가 telomere와 결합하는 부
분과 이를 표적으로 하는 라이보자임의 효과 검정 
 
여 말 희 
 
연세대학교 대학원 
의과학 사업단 
 
 
    Telemerase는 염색체 말단에 있는 telomere를 연장, 유지시켜주는 
역전사 효소이다. 사람의 telemere는 TTAGGG서열이 반복된 구조로
서 염색체 기능과 구조 유지에 필수적인 역할을 한다. 이러한 
telemere는 세포가 분열할 때 마다, DNA polymerase가 가지는 ‘end 
replication problem‘에 의해 점점 짧아진다. telomere가 일정길이 이상 
짧아진 세포는 더 이상 분열하지 못하고 노화나 세포사멸 기전에 
의해 제거되어진다. 하지만 정상 체세포와 달리 암세포에서는 
telomerase가 과발현됨으로서 끊임없이 성장, 분열하는 불멸화 능력
을 획득한다. 따라서 암치료에 있어 telomerase는 효과적이고 암세포 
특이적인 표적분자로 제시된다. 
Telomerase는 크게 두개의 구성요소로 이루어져 있다. 하나는 
역전사 효소 기능을 가지는 단백질 부분인 hTERT와 telemere의 주형
으로 역할을 하는 RNA인 hTR로 이루어져 있다. hTR은 모든 척추동
물에서 잘 보존된 이차 구조를 가지고 있으며 template, pseudoknot, 
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CR4-CR5, Box H/ACA, CR7와 같은 특징적인 구조로 이루어져 있다. 
본 연구는 hTR이 telomere와 결합하는데 필요한 domain에 대해 
알아보고자 하였고, 이것을 바탕으로 하여 이 domain을 억제할 수 
있는 ribozyme을 합성하여 항암요법으로서의 가능성을 알아보고자 
하였다. 먼저 hTR의 각 domain을 차례로 삭제한 truncation mutant를 
제작하였다. 이러한 mutant들이 telomere와 결합하는 능력을 
electrophoretic mobility shift assay (EMSA)로 시행하였다. 결과는 326nt
를 가지고 있는 mutant에서부터 결합이 관찰되었다. 따라서 hTR이 
telomere와 결합하는데 최소한 326nt가 필수적임을 알 수 있었다. 본 
연구자는 이 326nt내에 포함된 있으며 template, pseudoknot, CR4-CR5 
domain의 역할을 좀더 알아보고자 각각의 domain에 대한 antisense 
oligonucleotide를 제작하여 telomere와 결합하는 능력과 효소활성에 
미치는 영향을 알아보았다. 결과는 template에 대한 antosense 
oligonucleotide는 telomere와의 결합과 효소활성을 모두 효과적으로 
억제하였다. 반면 CR4-CR5에 대한 antisense oligonucleotide는 효소활
성은 효과적으로 억제하였으나 telomere와 결합하는데는 큰 영향을 
미치지 못하였다.  
이러한 in vitro 결과를 토대로 하여, hTR을 표적으로 하는 7개
의 ribozyme을 제작하였다.  7개의 ribozyme을 in vitro에서 합성한 hTR 
substrate와 반응 시킨 결과 R1 ribozyme에서 효과적으로 hTR이 잘려
짐을 관찰하였다. 따라서 R1을 발현하는 expression vector를 제작하
여 사람의 유방암 세포주인 MCF-7에 transfection하였다. 이 
transfectant로 부터  hTR의 발현이 감소하고 이에 의해 telomerese 효
소활성도가 감소되는 것을 관찰하였다. 긍극적으로 이러한 세포에서 
R1 ribozyme에 의해 암세포의 성장이 억제됨을 확인하였다. 
결론적으로 본 실험은 hTR이 telomere와 결합하는데 326nt가 
필수적임을 확인하였다. Antisense oligonucleotide 실험을 토대로 각각
의 domain은 telomerase가 활성화되는데 서로 다른 기능을 담당하고 
있음을 확인하였다. hTR의 template domain을 표적으로 한 R1 라이보
자임은 효과적으로 telomerese 활성과 암세포의 성장을 억제하였다. 
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따라서 hTR의 template domain은 암세포의 telomerase활성을 억제하는 
좋은 target site임을 확인하였다 
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